Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Trinity Biotech plc is a diagnostics & research business based in the US. Trinity Biotech shares (TRIB) are listed on the NASDAQ and all prices are listed in US Dollars. Trinity Biotech employs 543 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Experienced Investors
Our top pick for
Large Accounts
| Latest market close | $2.06 |
|---|---|
| 52-week range | $1.75 - $6.82 |
| 50-day moving average | $2.32 |
| 200-day moving average | $2.78 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.06 from 2021-10-20
| 1 week (2021-10-13) | -6.36% |
|---|---|
| 1 month (2021-09-21) | -9.25% |
| 3 months (2021-07-21) | 5.64% |
| 6 months (2021-04-21) | -42.30% |
| 1 year (2020-10-20) | -21.67% |
|---|---|
| 2 years (2019-10-18) | 157.69% |
| 3 years (2018-10-19) | 3.41 |
| 5 years (2016-10-20) | 7.07 |
Valuing Trinity Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Trinity Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Trinity Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Trinity Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Trinity Biotech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27.7 million.
The EBITDA is a measure of a Trinity Biotech's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $116.2 million |
|---|---|
| Operating margin TTM | 22.04% |
| Gross profit TTM | $48.6 million |
| Return on assets TTM | 12.63% |
| Return on equity TTM | -683% |
| Profit margin | -1.62% |
| Book value | $0.34 |
| Market capitalisation | $42.4 million |
TTM: trailing 12 months
There are currently 279,283 Trinity Biotech shares held short by investors – that's known as Trinity Biotech's "short interest". This figure is 0% up from 279,169 last month.
There are a few different ways that this level of interest in shorting Trinity Biotech shares can be evaluated.
Trinity Biotech's "short interest ratio" (SIR) is the quantity of Trinity Biotech shares currently shorted divided by the average quantity of Trinity Biotech shares traded daily (recently around 133628.22966507). Trinity Biotech's SIR currently stands at 2.09. In other words for every 100,000 Trinity Biotech shares traded daily on the market, roughly 2090 shares are currently held short.
However Trinity Biotech's short interest can also be evaluated against the total number of Trinity Biotech shares, or, against the total number of tradable Trinity Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trinity Biotech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Trinity Biotech shares in existence, roughly 10 shares are currently held short) or 0.018% of the tradable shares (for every 100,000 tradable Trinity Biotech shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trinity Biotech.
Find out more about how you can short Trinity Biotech stock.
We're not expecting Trinity Biotech to pay a dividend over the next 12 months.
Trinity Biotech's shares were split on a 1:4 basis on 1 June 2005. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trinity Biotech shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Trinity Biotech shares which in turn could have impacted Trinity Biotech's share price.
Over the last 12 months, Trinity Biotech's shares have ranged in value from as little as $1.75 up to $6.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trinity Biotech's is 1.6931. This would suggest that Trinity Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.